Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company was founded in 1832 and is based in Rogers, Connecticut.
ROG Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Rogers Corp. To summarize, we found that Rogers Corp ranked in the 39th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Rogers Corp ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is 7.31 -- which is good for besting 65.17% of its peer stocks (US stocks in the Technology sector with positive cash flow).
88% of the company's capital comes from equity, which is greater than 75.55% of stocks in our cash flow based forecasting set.
The business' balance sheet reveals debt to be 12% of the company's capital (with equity being the remaining amount). Approximately only 24.41% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Rogers Corp? See ACN, ALRM, EXLS, HPE, and TXN.
Shares of Roche Holding AG gained 2.4% in premarket trading on Thursday after the drugmaker said it is testing a combination of its rheumatoid arthritis drug Actemra with Gilead Sciences Inc.'s remdesivir in hospitalized COVID-19 patients. Gilead's stock was down 0.4%. Roche has previously announced it is studying Actemra in 450 hospitalized COVID-19 patients participating in a randomized, double-blind, placebo-controlled late-stage trial; results from that trial are expected "this summer," Roche said. The new Phase 3, randomized, double-blind, multicenter study will test Actemra and remdesivir against placebo and remdesivir in about 450 patients hospitalized with severe COVID-19 pneumonia. Trial sites are in Canada, Europe, and the U.S. The Food and Drug Administration granted an eme...
The head of Canada's largest wireless business says sales of new mobile phones have been very quiet and likely won't pick up until customers return to stores and malls that have been temporarily closed due to the pandemic.
Investors looking for a solid investment with growth and income-earning potential should strongly consider Rogers (TSX:RCI.B)(NYSE:RCI). The post It’s Time to Consider Rogers (TSX:RCI.B) appeared first on The Motley Fool Canada .
The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s remdesivir in combination with Eli Lilly & Co.'s rheumatoid arthritis drug Olumiant in COVID-19 patients as part of the next phase of the randomized, controlled clinical trial that led to the authorization of remdesivir. This study will enroll 1,000 people at more than 100 sites in the U.S. and abroad, to "examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients," NIAID director Dr. Anthony Fauci said in a statement. The topline results from the remdesivir trial helped make up the basis of the Food and Drug Administration's (FDA) emergency use authorization for the drug last week. A number of medicines that have be...